315 results on '"Ricciuti, B"'
Search Results
2. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
3. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
4. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
5. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
6. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
7. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
8. OA19.05 Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer
9. P2.05-08 Immunotherapy Prognostication with Thoracic CT Contrastive Self-Supervised Learning in Patients with Non-Small Cell Lung Cancer
10. P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer
11. MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma
12. AI-Derived CT Body Composition in Advanced Non-Small Cell Lung Cancer: A Multicohort Study
13. PO-2125 Contrastive self-supervised learning of lung tumor imaging predicts immunotherapy response
14. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
15. P3.12C.05 Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC.
16. P2.11B.02 Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer.
17. A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions
18. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
19. MA02.09 Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC
20. 1060P Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC
21. P1.15-03 Clinical Outcomes Among Patients with Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity
22. EP08.01-043 Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
23. P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade
24. P2.11A.12 Machine Learning-Based Clinicogenomic Prediction of Response to PD-(L)1 Inhibition in KRAS Altered Non-Small Cell Lung Cancer
25. OA18.06 Characteristics and Outcomes of Patients with SMARCA4-Deficient Undifferentiated Thoracic Tumors
26. 1352P Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
27. 1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
28. 1232P Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)
29. ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)
30. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes
31. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
32. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
33. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50
34. P3.12C.02 MET Fusions in NSCLC: Prevalence, Oncogenicity, and Resistance Mechanism
35. P2.11B.04 Chemotherapy Increases Acquired Resistance to Immunotherapy in NSCLC: A Metanalysis of Aggregate and Individual Patient Data
36. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
37. FP03.03 ECOG PS of 0-1 and Very High PD-L1 Expression ≥90% Are Associated With Clinical Benefit From First-Line Chemo-Immunotherapy in Advanced NSCLC
38. 2255P Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
39. 2198P Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
40. P33.04 Programmed Death-Ligand 1 (PD-L1) Changes in Non-Small-Cell Lung Cancer (NSCLC): Clinical, Pathologic, and Genomic Correlates
41. P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status
42. P14.21 Baseline Derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Clinical Outcomes to First-Line Pembrolizumab in NSCLC with High PD-L1 (≥50%)
43. P2.11B.03 Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy
44. Corrigendum: Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: A short review on the current evidence (Onco Targets Ther, 2019, 12, 3171–3179)
45. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >= 50%: a multicenter study with external validation
46. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >= 50%: a multicenter study with external validation
47. Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
48. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
49. P1.04-04 DNA Damage Response Gene Alterations Are Associated with High Tumor Mutational Burden and Clinical Benefit from PD-1 Axis Inhibition in NSCLC
50. P2.04-32 Comparison of Clinicopathological and Genomic Characteristics Between NSCLCs with a PD-L1 Tumor Proportion Score of ≥90% vs <1%
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.